StockNews.AI
SCPH
StockNews.AI
160 days

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

1. SCPH will host a conference call on March 19, 2025. 2. The call will discuss Q4 and full year 2024 financial results. 3. SCPH aims to revolutionize cardiorenal healthcare with innovative treatments. 4. The company focuses on patient-centric care to meet unmet needs. 5. Investors can access the call via their website.

Earnings
-0.99%Current Return
VS
-1.32%S&P 500
$3.0203/12 04:05 PM EDTEvent Start
$2.9903/13 10:36 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Expecting results announcements may lead to temporary price movements, but generally stable.

How important is it?

Upcoming earnings call carries potential for investor sentiment shift, dependent on financial results.

Why Short Term?

Immediate interest before and after upcoming financial results may spur trading activity, but long-term trends depend on performance.

Related Companies

AMGNVRTXCELG
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET March 12, 2025 16:01 ET  | Source: scPharmaceuticals Inc. BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About scPharmaceuticalsAt scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com. Katherine MirandascPharmaceuticals Inc., 781-301-6869kmiranda@scpharma.com Investors:Nick ColangeloGilmartin Group, 339-225-1047Nick@GilmartinIR.com

Related News